Bone alterations during HIV infection

New Microbiologica

Volumn 31, Issue 2, 2008, Pages 155-164

  De Crignis, Elisa ^a   Cimatti, Laura ^a   Borden, Marco ^a   Gibellini, Davide ^a   Re, Maria Caria ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bone lesion; HIV; Osteoblasts; Osteoclasts

Indexed keywords

ADULT; CHILD; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METABOLIC BONE DISEASE; OSTEOPOROSIS; REVIEW;

ADULT; BONE DISEASES, METABOLIC; CHILD; FEMALE; HIV INFECTIONS; HUMANS; MALE; OSTEOPOROSIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 46649097255     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. AMIEL C., OSTERTAG A., SLAMA L., BAUDOIN C., N'GUYEN T., LAJEUNIE E., NEIT-NGEILH L., ROZENBAUM W., DE VERNEJOUL M.C. (2004). BMD Is Reduced in HIV-Infected Men Irrespective of Treatment. Journal of Bone and Mineral Research. 19 (3), 402-409.
2. AMOROSA V., TEBAS P. (2003). Emerging bone problems in patients infected with human immunodeficiency virus. Clinical Infectious Diseases. 36, S101-S105.
3. AMOROSA V., TEBAS P. (2006). Bone disease and HIV infection. Clinical Infectious Diseases. 42, 108-114.
4. ANNAPOORNA N., RAO G.V., REDDY N.S., RAMBABU P., RAO K.R. (2004). An increased risk of osteoporosis during acquired immunodeficiecny syndrome. Int. J. Med. Sci. 3, 152-164.
5. ARNSTEN J.H., FREEMAN R., HOWARD A.A., FLORIS-MOORE M., LO Y., KLEIN R.S. (2007). Decreased bone mineral density and increased fracture risk in aging men with or at rick fro HIV infection. AIDS. 21, 617-623.
6. ARPADI S.M. (2000). Growth Failure in Children With HIV Infection. Journal of Acquired Immune Deficiency Syndromes. 25, S37-S42.
7. ARPADI S.M., HORLICK M., THORNTON J., CUFF P.A., WANG J., KOTLER D.P. (2002). Bone mineral content is lower in prepubertal hiv-infected children, journal of acquired immune deficiency syndromes. 29, 450-454.
8. AUKRUST P., HAUG C.J., UELAND T., LIEN E., MULLER F., ESPEVIK T., BOLLERSLEV J., FROLAND S.S. (1999). Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of thebone-remodeling process during highly active antiretroviral therapy. Journal of Endocrinology and Metabolism. 84 (1), 145-150.
9. BECKER C. (2006). Pathophysiology and clinical manifestations of osteoporosis. Clinical Cornerstone. 8 (1), 19-27.
10. BERG K.M., KLEIN R.S., SCHOENBAUM E.E., ARNSTEN J.H. (2007). Interpreting the association between HIV and bone mineral density. AIDS. 21, 785-786.
11. BIANCHI M.L. (2007). Osteoporosis in children and adolescents. Bone. 41, 486-495.
12. BINKLEY T.L., BERRY R., SPECKER B.L. (2008). Methods for measurement of pediatric bone. Rev Endocr Metab Disord. 21, 617-623.
13. BOLLAND M.J., GREY A.B., HORNE A.M., BRIGGS S.E., THOMAS M.G., ELLIS-PEGLER R.B., WOODHOUSE A.F., GAMBLE G.D., REID I.R. (2007). Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clinical Endocrinology. 67, 270-275.
14. BONGIOVANNI M., CHIESA E., RIVA A, D'ARMINIO-MONFORTE A., BINI T. (2003). Avascular necrosis of the femoral head in a HIV-1 infected patient receiving lopinavir/ritonavir. International Journal of Antimicrobial Agents. 22, 630-631.
15. BONGIOVANNI M., FAUSTO A., CICCONI P., MENICAGLI L., MELZI S., LIGABO V.E., CORNALBA G., BINI T., SARDANELLI F., D'ARMINIO MONFORTE A. (2005). Osteoporosis in HIV-infected subjects: a combined effect of highly active antiretro viral therapy and hiv itself? J Acquir Immune Defic Syndr. 40 (4), 503-504.
16. BONNICK S.L. (2006). Osteoporosis in men and women. Clinical Cornerstone. 8, 28-39.
17. Boyce B.F., Xing L. (2007). Biology of RANK, RANKL and osteoprotegerin. Arthritis Research and Therapy. 9, 405-407.
18. BOYLE W.J., SIMONET W.S., LACEY D. (2003). Osteoclast differentiation and activation. Nature. 423, 337-342.
19. BREEN E.C. (2002). Pro- and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome. Pharmacol Ther. 95 (3), 295-304.
20. BROWN T.T., QAQISH R.B. (2006). Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 20, 2165-2174.
21. BROWN T.T., QAQISH R.B. (2007). Response to Berg et al. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 21, 1829-1836.
22. BROWN T.T., RUPPE M.D., KASSNER R., KUMAR P., KEHOE T., DOBBS A.S., TIMPONE J. (2004). Reduced bone mineral density in human immunodeficiencyvirus-infected patients and its association with increased central adiposity and postload hyperglycemia. The Journal of Clinical Endocrinology and Metabolism. 89, 1200-1206.
23. BROWN T.T., QAQISH R.B. (2006b). Antiretroviral therapy and the prevalence of osteopenia osteoporosis: a meta-analytic review. AIDS. 20, 2165-2174.
24. BRUERA D., LUNA N., DAVID D.O., BERGOGLIO L.M., ZAMUDIO J. (2003). Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 17, 1917-1923.
25. CAMOZZI V., TOSSI A., SIMONI E., PAGANI F., FRANCUCCI C.M., MORO L. (2007). Role of biochemical markers of bone remodelling in clinical practice. J Endocrinol Invest. 30, 13-17.
26. CAMPBELL D.G., STEPHENSON A.J., LI P., OAKESHOTT R.D. (1996). Human immunodeficiency virus infection of human bone derived cells. Clinical Orthopaedics and Related Research. 331, 291-299.
27. CARR A., MILLER J., EISMAN J.A., COOPER D.A. (2001). Osteopenia in HIVinfected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. Clinical Orthopaedics and Related Research. 15, 703-709.
28. CASHMAN K.D. (2007). Diet, nutrition and bone health. The journal of Nutrition. 137, 2507S-2512S.
29. CAZANAVE C., DUPON M., LAVIGNOLLE- AURILLAC V., BARTHE N., LAWSON-AYAYI S., MEHSEN N., MERCIE P., MORLAT P., THIEBAUT R., DABIS F. (2008). Reduced bone mineral density in HIV infected patients: prevalence and associated factors. AIDS. 22, 395-402.
30. CHAKRAVARTI A., MARCEU A.A., FLAMAND L., POUBELLE P.E. (2007). Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro. Laboratory investigation. 78, 48251-48258.
31. CLOWES J.A., RIGGS B.L., KHOSLA S. (2005). The role of the immune system in the pathophysiology of osteoporosis. Immunological Reviews. 208, 207-227.
32. COLLIER J. (2007). Bone disorders in chronic liver. Hepatology. 46, 1271-1278.
33. COOPER O.B., BROWN T.T., DOBS A.S. (2003). Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clinical Infectious Diseases. 37, S132-S136.
34. COTTER E.J., MALIZIA A.P., CHEW N., POWDERLY W.G., DORAN P.P. (2007). HIV proteins regulate bone markers secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Research and Human Retrovirus. 23, 1521-1529.
35. COZZOLINO M., VIDAL M., ARCIDIACONO M.V., TEBAS P., YARASHESKI E.K., DUSSO A.S. (2003). HIV protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 17, 513-520.
36. CUMMINGS S.R., MELTON L.J. III. (2002). Epidemiology and outcomes of osteoporotic fractures. The Lancet. 359, 1761-1767.
37. DUMMINGS S.R., BATES D., BLACK D.M. (2002). Clinical use of bone densitometry. JAMA. 288 (15), 1889-1898.
38. DENNISON E., MOHAMED M. ABDIN, COOPER C. (2006). Epidemiology of osteoporosis. Rheum Dis Clin N Am. 32, 617-629.
39. DOLAN S.E., KANTER J.R., GRINSPOON S. (2006). Longitudinal analysis of bone density in human immunodeficiency virus-infected women. The Journal of Clinical Endocrinology and Metabolism. 91, 2938-2945.
40. DOLAN S.E., CARPENTER S., GRINSPOON S. (2007). Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women. Journal of Acquired Immune Deficiency Syndrome. 45 (2), 161-168.
41. DUBE M.P., QIAN D., EDMONSON-MELANCON H.E., SATTLER F.R., GOODWIN D., MARTINEZ C., WILLIAMS V., BUCHANAN T.A., JONSHON D. (2002). Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir based antiretroviral therapy. Clinical Infectious diseases. 35, 475-481.
42. FAIRFIELD W.P., FINKELSTEIN J.S., KLIBANSKI, A., GRINSPOON S.K. (2001). Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. The Journal of Clinical Endocrinology and Metabolism. 86 (5), 2020-2026.
43. FAKRUDDIN J.M., LAURENCE J. (2003). HIV envelope gp 120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kB ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon α/RANKL cross-talk. The Journal of Biological Chemistry. 78 (48), 48251-48258.
44. FAKRUDDIN J.M., LAURENCE J. (2004). Interactions among human immunodeficiency virus (HIV)-1, interferon- and receptor of activated NF-kB ligand (RANKL): implications for HIV pathogenesis. Clin Exp Immunol. 137, 538-545.
45. FAKRUDDIN J.M., LAURENCE J. (2005). HIV-1 Vpr enhances production of receptor of activated NF-B ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol. 150, 67-78.
46. FAUSTO A., BONGIOVANNI M., CICCONI P., MENICAGLI L., LIGABO E.V., MELZI S., BINI T., SARDANELLI F., CORNALBA G.P., D'ARMINIO MONFORTE A. (2006). Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 38, 893-897.
47. FERNANDEZ-RIVERA J., GARCIA R., LOZANO F, MACIAS J., GARCIA-GARCIA J.A., MIRA J.A., CORZO I.E., GOMEZ-MATEOS J., RUEDA A., SANCHEZ-BURSON J., PINEDA J.A. (2003). Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trias. 3, 337-346.
48. GALLANT J.E., STASZEWSKI S., POZNIAK A.L., DE JESUS E. SULEIMAN J.M., MILLER M.D., COAKLEY D.F., LU B., TOOLE J.J., CHENG A.K., 903 STUDY GROUP. (2004). Efficacy and safety of tenofovir DF vs stavudine in combinationtherapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 14, 292 (2), 191-201.
49. GARCIA APARJCIO A.M., MUÑOZ FERNANDEZ S., GONZALEZ J., ARRIBAS J.R., PENA J.M., VAZQUEZ J.J., MARTINEZ M.E., COYA, J., & MOLA, E. MARTIN. (2006). Abnormalities in the bone mineral metabolism in HIV-infected patients. Clinical Rheumatology. 25, 537-539.
50. GIBELLINI D., BORDERI M., DE CRIGNIS E., CICOLA R., VESCINI F., CAUDARELLA R., CHIODO F., RE M.C. (2007). RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HTV-1-positive men. J Med Virol. 79 (10), 1446-1454.
51. GIBELLINI D., VITONE F., BUZZI M., SCHIAVONE P., DE CRIGNIS E., CICOLA R., CONTE R., PONTI C., RE M.C. (2007). HIV-1 negatively affects the survival/maturation of cord blood CD34(+) hematopoietic progenitor cells differentiated towards megakaryocytic lineage by HIV-1 gp120/CD4 membrane interaction. J Cell Physiol. 210 (2): 315-324.
52. GKRANIA-KLOTSAS E., KLOTSAS A.E. (2007). HIV and HW treatment: effects on fats, glucose and lipids. British Medical Bullettin. 84, 49-68.
53. GLESBY M.J. (2003). Bone disorders in human immunodeficiency virus infection. Clinical Infectious Diseases. 37, S91-S95.
54. GUARALDI G., VENTURA P., ALBUZZA M., ORLANDO G., BEDINI A., AMORICO G., ESPOSITO R. (2001). Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS. 15, 137-138.
55. GUARALDI G., ORLANDO G., MADEDDU G., VESCINI F., VENTURA P., CAMPOSTRINI S., MURA M.S., PARISE N., CAUDARELLA R., ESPOSITO R. (2004). Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials. 5, 269-277.
56. HARADA S.I., RODAN G.A. (2003). Control of osteoblast function and regulation of bone mass. Nature. 423, 349-355.
57. HUANG J.S., WILKIE S.J., SULLIVAN M.P., GRINSPOON S. (2001). Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting. The Journal of Clinical Endocrinology and Metabolism. 86 (8), 3533-3539.
58. JACOBSON D.L., SPIEGELMAN D., DUGGAN C., WEINBERG G.A., BECHARD L., FURUTA L., NICCHITTA J., GORBACH S. L., MILLER T.L. (2005). Predictors of bone mineral density in human immunodeficiency virus-1 infected children. Journal of Pediatric Gastroenterology and Nutrition. 41 (2), 339-346.
59. JAIN R.G., LENHARD J.M. (2002). Select HIV protease inhibitors alter bone and fat metabolism ex vivo. The Journal of Biological Chemistry. 277, 19247-19250.
60. JOHNELL O., KANIS J.A., ODEN A., JOHANSSON H., DELMAS C. DE LAETAND P., EISMAN J. A., FUJIWARA S., KROGER H., MELLSTROM D., MEUNIER P.J., MELTON L.J., ONEIL T., POLS H., REEVE J., SILMAN A., TENENHOUSE A. (2005). Predictive value of BMD for Hip and other fractures. Journal of Bone and Mineral Research, 20 (7), 1185-1194.
61. KANISN J.A., MCCLOSKEY E.V., JOHANSSON H., ODEN A., MELTON L.J., KHALTAEV N. (2008). A reference standard for the description of osteoporosis. Bone. 42, 467-475.
62. KNOBEL H., GUELAR A., VALLECILLO G., NOGUAOS X., DAEZ A. (2001). Osteopenia in HIV-infected patients: is it the disease or is it the treatment. AIDS. 15, 807-808.
63. KONG Y.Y., PENNINGER J.M. (2000). Molecular control of bone remodelling and osteoporosis. Experimental Gerontology. 35, 947-956.
64. KONISHI M., TAKANISHI K., YOSHIMOTO E., UNO K., KASAHARA K., MIKASA K. (2005). Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients. AIDS. 19 (11), 1240-1241.
65. LANDONIO S., QUIRINO T., BONFANTI P., GABRIS A., BOCCASSINI L., GULISANO C., VULPIO L., RICCI E., CARRABBA M., VIGEVANI G.M. (2004). Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART. Biomedicine and Pharmacotherapy. 58, 505-508.
66. LAWAL A., ENGELSON E., WANG J., HEYMSFIELD S.B., KOTER D.P. (2001). Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS. 15, 278-279.
67. LI Y., TORALDO G., LI A., YANG X., ZHANG H., QIAN W.P., WEITZMANN M.N. (2007). B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood. 109 (9), 3839-3848.
68. LIM D., RIEDER M.J. (2008). Interventions for the treatment of decreased bone mineral density associated with HIV infection. The Cochrane Library. 1, 1-26.
69. LOISEAU-PERES S., DELAUNAY C., LESPESSAILLES E., BALLOUCHE N., ARSAC P., BENHAMOU C.L. (2002). Osteopenia in patients infected by the human immunodeficiency virus. A case control study. Clinical Infectious Diseases. 69, 482-485.
70. MACKEY D.C., LI-YOUNG L., CAWTHON P.M., BAUER D.C., NEVITT M.C., CAULEYM J.A., HILLIER T.A., LEWIS C.E., BARRET-CONNOR E., CUMMINGS S.R. (2007). High-trauma fractures and low bone mineral density in older women and men. JAMA. 298 (20), 2381-2388.
71. MADEDDU G., SPANU A., SOLINAS P., CALIA G.M., LOVIGU C., CHESSA F., MANNAZZU M., FALCHI A., MURA M.S., MADEDDU G. (2004). Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. J Nucl Med Mol Imaging. 48, 39-48.
72. MALIZIA A.P., COTTER E., CHEW N., POWDERLY W.G., DORAN P.P. (2007). HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. AIDS Res Hum Retroviruses. 23, 243-250.
73. MALLON P.W.G., MILLER J., COOPER D.A., CARR A. (2003). Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 17, 971-979.
74. MARTIN K., LAWSON-AYAYI S., MIREMONT-SALAME G., BLAIZEAU M.J., BALESTRE E., LACOSTE D., RAGNAUD J.M., MALVY D., DUPON M., MERCIE P., SCHAEVERBEKR T., HARAMBURU F., DABIS F. (2004). Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitane cohort. HIV Medicine. 5, 421-426.
75. MCCOMSEY G.A., KENDALL M.A., TEBAS P., SWINDELLS S., HOGG E., ALSTON-SMITH B., SUCKOW C., GOPALAKRISHNAN G., BENSON C., WOHL D.A. (2007). Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 21, 2473-2482.
76. MELISSA L., KNOTHE T., ADAMSON J.R., TAMI A.E., BAUER T.W. (2004). The osteocyte. The International Journal of Biochemistry and Cell Biology. 36, 1-8.
77. MELLERT W., KLEINSCHMIDT A., SCHMIDT J., FESTL H., EMLER S., ROTH W.K., ERFLE V. (1990). Infection of human fibroblasts and osteoblast-like cells with HTV-1. AIDS. 6, 527-535.
78. MOE S., DRUEKE T., CUNNINGHAM J., GOODMAN W., MARTIN K., OLGAARD K., OTT S., SPRAGUE S., LAMEIRE N., EKNOYAN G. (2006). Definition, evaluation and classification of renal osteodystrophy: a positive statemene from kidney disease: improving global outcomes. Kidney International. 69, 1945-1953.
79. MONDY K., YARASHESKI K., POWDERLY W.G., WHYTE M., CLAXTON S., DE MARCO D., HOFFMANN M., TEBAS P. (2003). Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clinical Infectious Disease. 36, 482-490.
80. MONDY K., POWDERLY W.G., CLAXTON S., YARASHESKI K., ROYAL M., STONEMAN J.S., HOFFMANN M., TEBAS P. (2005). Alendronate, vitamin D and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. Journal of Acquired Immunde Deficiency Syndrome. 38, 426-431.
81. MORA S., SALA N., BRICALLI D., ZUIN G., CHIUMELLO G., VIGANO A. (2001). Bone mineral loss through increased bone turnover in HIV-infected children treated with higly active antiretroviral therapy. AIDS. 15, 1823-1829.
82. MORA S., ZAMPRONI I., BECCIO S., BIANCHI R., GIACOMET V., VIGANO A. (2004). Longitudinal changes of bone mineral density and metabolism in antiretroviraltreated human immunodeficiency virus-infected children. The Journal of Endocrinology and Metabolism. 89, 24-28.
83. MORA S., ZAMPRONI I., CAFARELLI L., GIACOMET V., ERBA P., ZUCCOTTI G., VIGANO A. (2007). Alterations in circulatin osteoimmune factors may be responsible for high bone resorption rate in HIV- infected children and adolescents. AIDS. 21, 1129-1135.
84. NACHER M., SERRANO S., GONZALEZ A., HERNANDEZ A., MARINOSO M.L., VILELLA R., HINAREJOS P., DIEZ A., AUBIA J. (2001). Osteoblasts in HIV-infected patients: HIV-1 infection and cell function. AIDS. 15, 2239-2243.
85. NOLAN D., UPTON R., MCKINNON E., JOHN M., JAMES., ADLER B., ROFF G., VASIKARAN S., MALLAL S. (2001). Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 15, 1275-1280.
86. O'BRIEN K.O, RAZAVI M., HENDERSON R.A., CABALLERO B., ELLIS K.J. (2001). Bone mineral content in girls perinatally infected with HIV. The Journal of Clinical Nutrition. 73, 821-826.
87. PAN G., WU X., MCKENNA M.A., FENG X., NAGY T.R., MCDONALD J.M. (2004). AZT enhances osteoclastogenesis and bone loss. Osteoporosis Int. 20, 608-620.
88. PAN G., KILBY M., MCDONALD J.M. 2006. Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses, 22, 1131-1141.
89. PARSONAGE M.J., WILKINS E.G.L, SNOWDEN N., ISSA B.G. SAVAGE M.W. (2005). The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Medicine. 6, 341-346.
90. PATON N.I.J., MACALLAN D.C., GRIFFIN G.E., PAZIANAS M. (1997). Bone mineral density in patients with human immunodeficiency virus infection. Clcif Tissue Int. 61, 30-32.
91. PITUKCHEEWANONT P., SAFANI D., CHURCH J., GILSANZ V. (2005). Bone measures in HIV-1 infected children and adolescents: disparity between quantitative computed tomography and dual energy X ray adsorptiometry measurements. Osteoporosis Int. 16, 1393-1396.
92. PRIOR J., BURDGE D., MAAN E., MILNER R., HANKINS C., KLEIN M., WALMSLEY S. (2007). Fragility fractures and bone mineral density in HIV positive women: a case control population-based study. Osteoporosis Int. 18, 1345-1353.
93. ROTHFUSS K.S., STANGE E.F., HERRLINGER K.R. (2006). Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 14 4819-4831.
94. SEMINARI E., CASTAGNA A., SOLDARINI A., GALLI L., FUSETTI G., DORIGATTI F., HASSON H., DANISE A., GUFFANTI M., LAZZARIN A., RUBINACCI A. (2005). Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Medicine. 6, 145-150.
95. SERRANO S., MARINOSO M.L., SORIANO J.C., RUBIES-PRAT J., AUBIA J., COLL J., BOSCH J., RIO L. DEL VILA, J., GODAY A., NACHER M. (1995). Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone. 16 (2), 185-191.
96. SORENSEN M.G., HENRIKSEN K., DZIGIEL M.H., TANKO L.B., KARSDAL M.A. (2006). Estrogen directly attenuates human osteoclastogenesis, but has no effecton resorption by mature osteoclasts, Clinical Infectious Diseases. 25, 475-483.
97. STAZI A.V., TRECCA A., TRINTI B. (2008). Osteoporosis in celiac disease and in endocrine and reproductive disorders. World J Gastroenterol. 14 (4), 498-505.
98. STROTMEYER E.S., CAULEY J.A. (2007). Diabetes mellitus, bone mineral density and fracture risk. Curr Opin Endocnnol Diabetes Obes. 14, 429-435.
99. TEBAS P., POWDERLY W.G., CLAXTON S., MARIN D., TANTISIRIWAT W., TEITELBAUM S.L., YARASHESKI K.E. (2000). Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. Metabolism. 14, F63-F67.
100. TEICHMANN J., STEPHAN E., DISCHER T., LANGE U., FEDERLIN K., STRACKE H., FRIESE G., LOHMEYER J., BRETZEL R.G. (2000). Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiencyvirus infection. Metabolism. 9, 1134-1139.
101. TEICHMANN J., STEPHAN E., LANGE U., DISCHER T., FRIESE G., LOHMEYER J., STRACKE H., BRETZEL, R.G. (2003). Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. Journal of Infection. 46, 221-227.
102. THOMAS J., DOHERTY S.M. (2003), HIV-infection: a risk factor for osteoporosis. Journal of Acquired Immune Syndrome. 33, 281-291.
103. TOMAZIC J., UL K., VOLCANSEK G., GORENSEK S., PFEIFER M., KARNER P., PREZELJ J., VIDMAR G., VIDMAR L. (2007). Prevalence and risk factors for osteopenia/osteoporosis in an HIV-infected male population. Wien Klin Wochenschr. 119, 639-646.
104. UELAND T., BOLLERSLEV J., GODANG K., MULLER F., FROLAND S.S., AUKRUST P. (2001). Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - possible role in bone homeostasis. European Journal of Endocrinology. 145, 685-690.
105. VERWEEL G., VAN ROSSUM A.M.C., HARTWIG N.G., WOLFS T.F.W., SCHERPBTER H.J., DE GROOT R. (2007). Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with sustained effect on growth. Osteoporosis Int. 109 (2), 1-7.
106. VESCINI F., BORDERI M., BUFFA A., SINICROPI G., TAMPELLINI L., CHIODO F., CAUDARELLA R. (2005). Bone mass in HIV-infected patients: focus on the role of therapy and sex. J Acquir Immune Defic Syndr. 33, 405-407.
107. Wang L., Mondal D., Russa V.F. La, Agrawal K.C. (2002). Suppression of clonogenic potential of human bone marrow mesenchymal stem cells by HIV type 1: putative role of HIV type 1 tat protein and inflammatory cytokines. Metabolism. 18, 917-931.
108. WHO (1994). Assesment of fracture risk and its application to screening for postmenopausal osteoporosis: report of WHO study group. WHO Tecnical Report Series. 1-129.
109. YIN M., DOBKIN J., BRUDNEY K., BECKER C., ZADEL J.L., MANANDHAR M., ADDESSO V., SHANE E. (2005). Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporosis Int. 16, 1345-1352.